Following the inauguration of its first US manufacturing site in Cranbury, New Jersey, in September, Biocon has announced that the facility, aimed at enhancing capacity and supply chain efficiency in the region, recently underwent a Good Manufacturing Practice (GMP) inspection by the US FDA.

The inspection concluded with a single observation, which the company will address within the stipulated timeframe, and it is not expected to impact ongoing business operations.

The Cranbury facility marks a strategic milestone for Biocon in the US, enabling faster access to its vertically integrated portfolio of therapies and benefiting patients in the region.

Some products have already been commissioned from the site, with additional launches planned in the near future. The facility is expected to play a critical role in advancing Biocon’s mission of expanding access to high-quality, affordable therapies worldwide.